|
|
|
Volumn 16, Issue 6 Suppl, 2010, Pages
|
|
Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTEGRIN;
MONOCLONAL ANTIBODY;
NATALIZUMAB;
ARTICLE;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
DISEASE COURSE;
DRUG ANTAGONISM;
DRUG MONITORING;
HUMAN;
MULTIPLE SCLEROSIS;
PATIENT SELECTION;
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
RISK FACTOR;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS AS TOPIC;
DISEASE PROGRESSION;
DRUG MONITORING;
HUMANS;
INTEGRIN ALPHA CHAINS;
LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;
MULTIPLE SCLEROSIS;
PATIENT SELECTION;
RISK FACTORS;
|
|
EID: 77958136697
PISSN: None
EISSN: 19362692
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (9)
|
|
References (0)
|
